CODX vs INCY · rev $3.9M vs P/E 14, rev $4.24B
Co-Diagnostics, Inc. Common Stock (CODX) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported INCY revenue for 2024-12-31 was $4.24B. Net income was $32.6M. Revenue was up 14.8% from 2023-12-31 to 2024-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
CODX currently screens at market cap $31.4M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the CODX and INCY stock pages for the full models.
Not investment advice.